Last 7 days
-1.2%
Last 30 days
-24%
Last 90 days
-3.9%
Trailing 12 Months
-45.2%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-09-28 | Kelly Jason R | sold | -174,900 | 1.749 | -100,000 | see remarks |
2023-09-28 | Canton Barry | sold | -65,887 | 1.75 | -37,650 | - |
2023-09-28 | Shetty Reshma P. | sold | -65,887 | 1.75 | -37,650 | see remarks |
2023-09-27 | Shetty Reshma P. | sold | -68,899 | 1.83 | -37,650 | see remarks |
2023-09-27 | Canton Barry | sold | -68,899 | 1.83 | -37,650 | - |
2023-09-27 | Kelly Jason R | sold | -182,500 | 1.825 | -100,000 | see remarks |
2023-09-21 | Kelly Jason R | sold | -176,600 | 1.766 | -100,000 | see remarks |
2023-09-21 | Canton Barry | sold | -66,452 | 1.765 | -37,650 | - |
2023-09-21 | Shetty Reshma P. | sold | -66,452 | 1.765 | -37,650 | see remarks |
2023-09-20 | Shetty Reshma P. | sold | -69,238 | 1.839 | -37,650 | see remarks |
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-09-26 | BROOKFIELD Corp /ON/ | new | - | 21,604 | 21,604 | -% |
2023-09-20 | BARCLAYS PLC | reduced | -55.97 | -401,000 | 644,000 | -% |
2023-09-08 | TUCKER ASSET MANAGEMENT LLC | new | - | 1,860 | 1,860 | -% |
2023-08-23 | WOLVERINE TRADING, LLC | added | 151 | 56,767 | 77,767 | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | added | 26.51 | 1,087,050 | 2,500,150 | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | added | 4.41 | 175,770 | 556,647 | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | reduced | -15.52 | 54.00 | 286 | -% |
2023-08-21 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | unchanged | - | 486,000 | 1,703,000 | 0.02% |
2023-08-17 | Coastal Bridge Advisors, LLC | new | - | 669,600 | 669,600 | 0.16% |
2023-08-17 | Coastal Bridge Advisors, LLC | unchanged | - | 888 | 2,832 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 14, 2023 | che austin | 6.3% | 99,857,282 | SC 13G/A | |
Feb 14, 2023 | knight thomas f. jr. | 5.0% | 74,936,116 | SC 13G/A | |
Feb 14, 2023 | anchorage capital group, l.l.c. | 4.83% | 69,904,593 | SC 13G/A | |
Feb 14, 2023 | viking global investors lp | 9.36% | 143,085,126 | SC 13G/A | |
Feb 13, 2023 | general atlantic, l.p. | 2.4% | 32,319,896 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 7.49% | 101,521,280 | SC 13G | |
Jan 25, 2023 | shetty reshma p. | 12.0% | 195,788,523 | SC 13D/A | |
Jan 25, 2023 | kelly jason r | 6.2% | 97,017,435 | SC 13D/A | |
Jan 23, 2023 | baillie gifford & co | 18.03% | 244,176,643 | SC 13G/A | |
Jul 01, 2022 | viking global investors lp | 9.7% | 115,084,128 | SC 13G |
Date Filed | Form Type | Document | |
---|---|---|---|
Oct 02, 2023 | 144 | Notice of Insider Sale Intent | |
Oct 02, 2023 | 144 | Notice of Insider Sale Intent | |
Oct 02, 2023 | 144 | Notice of Insider Sale Intent | |
Sep 29, 2023 | 4 | Insider Trading | |
Sep 29, 2023 | 4 | Insider Trading | |
Sep 29, 2023 | 4 | Insider Trading | |
Sep 29, 2023 | 144 | Notice of Insider Sale Intent | |
Sep 28, 2023 | 144 | Notice of Insider Sale Intent | |
Sep 28, 2023 | 144 | Notice of Insider Sale Intent | |
Sep 28, 2023 | 144 | Notice of Insider Sale Intent |
75.2%
75.2%
72.1%
Y-axis is the maximum loss one would have experienced if Ginkgo Bioworks Holdings was unfortunately bought at previous high price.
Income Statement (Last 12 Months) | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2019Q4 |
Revenue | -16.4% | 325,953,000 | 390,003,000 | 477,706,000 | 527,915,000 | 539,127,000 | 438,145,000 | 313,837,000 | 197,401,000 | 133,093,000 | 119,276,000 | 76,657,000 | 53,208,000 | 54,184,000 |
Operating Expenses | -24.6% | 1,613,378,000 | 2,141,056,000 | 2,686,658,000 | 4,188,821,000 | 3,573,684,000 | 2,884,868,000 | 2,142,304,000 | 397,021,000 | 340,454,000 | 315,830,667 | 213,684,000 | 190,860,000 | 125,782,000 |
S&GA Expenses | -50.1% | 446,925,333 | 895,040,000 | 1,429,799,000 | - | 1,665,349,333 | - | 862,952,000 | 62,521,333 | - | 37,077,333 | 19,762,000 | 39,504,000 | 29,483,000 |
R&D Expenses | -16.3% | 747,656,000 | 893,433,000 | 1,052,643,000 | 1,858,240,000 | 1,651,681,000 | 1,413,653,000 | 1,149,662,000 | 225,828,000 | 208,877,000 | 209,128,000 | 159,767,000 | 144,280,000 | 96,299,000 |
EBITDA | 100.0% | - | -1,665,891,000 | -2,078,741,000 | -3,490,597,000 | -3,033,922,000 | -2,220,765,145 | -1,818,701,000 | -135,043,545 | -145,464,211 | -62,942,200 | -98,777,000 | -58,161,333 | -157,317,000 |
EBITDA Margin | 100.0% | - | -4.27 | -4.35 | -6.61 | -5.63 | -5.07 | -5.80 | -0.68 | -1.09 | -0.82 | -1.29 | -1.09 | -2.90 |
Interest Expenses | 77.3% | 27,723,000 | 15,638,000 | 106,000 | 11,761,000 | 5,413,000 | 2,671,000 | 2,373,000 | -1,792,000 | 7,029,000 | 10,009,333 | 2,385,000 | 33,172,000 | 2,421,000 |
Earnings Before Taxes | 28.7% | -1,236,142,000 | -1,733,509,000 | -2,121,399,000 | -3,538,153,000 | -2,971,682,000 | -2,355,962,000 | -1,838,122,000 | -278,835,000 | -202,343,000 | -196,597,333 | -124,834,000 | -104,480,000 | -119,835,000 |
EBT Margin | 100.0% | - | -4.44 | -4.44 | -6.70 | -5.51 | -5.50 | -5.86 | -1.27 | -1.30 | -1.16 | -1.63 | -1.96 | -2.21 |
Net Income | 28.8% | -1,223,883,000 | -1,719,393,000 | -2,104,929,000 | -3,529,041,000 | -2,961,867,000 | -2,346,983,000 | -1,830,047,000 | -229,396,000 | -153,570,000 | -128,359,000 | -80,258,000 | -107,004,000 | -119,327,000 |
Net Income Margin | 100.0% | - | -4.41 | -4.41 | -6.68 | -5.49 | -5.48 | -5.83 | -1.03 | -0.95 | -0.64 | -1.05 | -2.01 | -2.20 |
Free Cashflow | 100.0% | - | -391,017,000 | -304,469,000 | -344,778,000 | -313,676,000 | -311,411,562 | -310,339,000 | -159,097,000 | -197,898,666 | -58,761,876 | -57,821,000 | -153,198,666 | -66,882,000 |
Balance Sheet | (In Millions) | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2019Q4 |
Assets | -5.2% | 2,292 | 2,417 | 2,539 | 1,871 | 1,994 | 2,058 | 2,071 | 2,151 | 1,726 | 1,728 | 675 | 697 |
Current Assets | -7.8% | 1,223 | 1,327 | 1,450 | 1,462 | 1,599 | 1,706 | 1,723 | 1,811 | 1.00 | 3.00 | 427 | 512 |
Cash Equivalents | -8.3% | 1,106 | 1,206 | 1,316 | 1,303 | 1,377 | 1,493 | 1,550 | 1,739 | 236 | 308 | 381 | 495 |
Inventory | -84.4% | 0.00 | 3.00 | 4.00 | 6.00 | 8.00 | 9.00 | 3.00 | 3.00 | - | - | 3.00 | - |
Net PPE | -6.3% | 294 | 314 | 315 | 188 | 176 | 149 | 146 | 143 | - | - | 121 | 63.00 |
Goodwill | 0.2% | 59.00 | 59.00 | 60.00 | 29.00 | 31.00 | 21.00 | 21.00 | 17.00 | - | - | 2.00 | 2.00 |
Liabilities | -2.6% | 788 | 810 | 803 | 431 | 427 | 444 | 504 | 533 | 255 | 150 | 205 | 195 |
Current Liabilities | -14.8% | 163 | 192 | 173 | 125 | 135 | 159 | 135 | 90.00 | 5.00 | 1.00 | 73.00 | 40.00 |
Shareholder's Equity | -6.5% | 1,504 | 1,608 | 1,736 | 1,435 | 1,572 | 1,619 | 1,567 | 1,618 | 356 | 396 | 470 | 502 |
Retained Earnings | -3.8% | -4,775 | -4,602 | -4,397 | -4,226 | -3,557 | -2,888 | -2,297 | -697 | -101 | 5.00 | -467 | -341 |
Additional Paid-In Capital | 1.1% | 6,281 | 6,212 | 6,136 | 5,669 | 5,098 | 4,471 | 3,805 | 2,250 | 106 | - | 929 | - |
Shares Outstanding | - | 1,933 | - | - | 1,631 | 1,621 | 1,607 | 1,611 | 1,324 | 1,293 | 1,290 | 1,289 | 1,256 |
Minority Interest | - | - | - | - | 5.00 | 32.00 | 33.00 | 62.00 | 66.00 | - | - | 9.00 | 9.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2019Q4 |
Cashflow From Operations | 8.0% | -297 | -322 | -252 | -313 | -290 | -225 | -253 | -88.28 | -110 | -96.26 | - | -101 | -44.66 |
Share Based Compensation | -40.3% | 806 | 1,351 | 1,931 | 3,414 | 2,851 | 2,259 | 1,606 | 15.00 | 20.00 | 0.00 | 0.00 | 0.00 | 1.00 |
Cashflow From Investing | 6.8% | -47.38 | -50.82 | -67.39 | -92.91 | -76.93 | -86.20 | -73.26 | -106 | -101 | -103 | -67.12 | -51.05 | -74.60 |
Cashflow From Financing | -0.6% | 95.00 | 96.00 | 95.00 | -13.64 | 1,535 | 1,533 | 1,534 | 1,545 | -3.66 | -1.24 | 90.00 | 121 | 410 |
Buy Backs | - | - | - | - | - | - | - | 25.00 | 100 | - | - | - | - | 0.00 |
Condensed Consolidated Statement of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | |||||||
---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | [1] | |||||
Biosecurity revenue: | |||||||||
Total Revenue | $ 80,568 | $ 144,618 | $ 161,270 | $ 313,023 | |||||
Costs and operating expenses: | |||||||||
Research and development | 144,282 | 290,059 | 306,921 | 613,635 | |||||
General and administrative | 102,341 | 438,427 | 213,774 | 873,195 | |||||
Total operating expenses | 264,719 | 792,397 | 561,166 | 1,636,173 | |||||
Loss from operations | (184,151) | (647,779) | (399,896) | (1,323,150) | |||||
Other income (expense): | |||||||||
Interest income, net | 14,349 | 2,264 | 28,894 | 2,441 | |||||
Loss on equity method investments | (67) | (10,166) | (1,516) | (31,053) | |||||
Loss on investments | (2,121) | (38,673) | (8,491) | (38,223) | |||||
Change in fair value of warrant liabilities | (4,482) | 23,509 | (3,278) | 108,544 | |||||
Gain on deconsolidation of subsidiary | 0 | 0 | 0 | 15,900 | |||||
Other income, net | 3,224 | 230 | 6,152 | 2,149 | |||||
Total other income (expense), net | 10,903 | (22,836) | 21,761 | 59,758 | |||||
Loss before income taxes | (173,248) | (670,615) | (378,135) | (1,263,392) | |||||
Income tax expense (benefit) | 67 | (45) | 149 | (229) | |||||
Net loss | (173,315) | (670,570) | (378,284) | (1,263,163) | |||||
Loss attributable to non-controlling interest | 0 | (1,745) | 0 | (3,833) | |||||
Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders | $ (173,315) | $ (668,825) | $ (378,284) | $ (1,259,330) | |||||
Net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders: | |||||||||
Basic | $ (0.09) | $ (0.41) | $ (0.2) | $ (0.78) | |||||
Diluted | $ (0.09) | $ (0.41) | $ (0.2) | $ (0.78) | |||||
Weighted average common shares outstanding | |||||||||
Basic | 1,933,437 | 1,620,704 | 1,924,251 | 1,614,138 | |||||
Diluted | 1,933,437 | 1,620,704 | 1,924,251 | 1,614,138 | |||||
Comprehensive loss: | |||||||||
Net loss | $ (173,315) | $ (670,570) | $ (378,284) | $ (1,263,163) | |||||
Other comprehensive income (loss): | |||||||||
Foreign currency translation adjustment | 314 | (3,141) | 1,332 | (3,781) | |||||
Total other comprehensive income (loss) | 314 | (3,141) | 1,332 | (3,781) | |||||
Comprehensive loss | (173,001) | (673,711) | (376,952) | (1,266,944) | |||||
Product [Member] | |||||||||
Biosecurity revenue: | |||||||||
Total Revenue | 10,788 | 3,887 | 22,454 | 17,834 | |||||
Costs and operating expenses: | |||||||||
Cost of Biosecurity revenue | 2,034 | 2,444 | 6,575 | 10,539 | |||||
Service [Member] | |||||||||
Biosecurity revenue: | |||||||||
Total Revenue | 24,497 | 96,489 | 59,437 | 229,459 | |||||
Costs and operating expenses: | |||||||||
Cost of Biosecurity revenue | 16,062 | 61,467 | 33,896 | 138,804 | |||||
Cell Engineering revenue [Member] | |||||||||
Biosecurity revenue: | |||||||||
Total Revenue | [2] | $ 45,283 | $ 44,242 | $ 79,379 | $ 65,730 | ||||
|
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 1,105,787 | $ 1,315,792 |
Accounts receivable, net | 68,019 | 80,907 |
Accounts receivable - related parties | 899 | 1,558 |
Inventory, net | 391 | 4,364 |
Prepaid expenses and other current assets | 48,357 | 47,458 |
Total current assets | 1,223,453 | 1,450,079 |
Property, plant, and equipment, net | 294,244 | 314,773 |
Operating lease right-of-use assets | 391,430 | 400,762 |
Investments | 119,944 | 112,188 |
Equity method investments | 1,120 | 1,543 |
Intangible assets, net | 105,033 | 111,041 |
Goodwill | 58,829 | 60,210 |
Other non-current assets | 97,946 | 88,725 |
Total Assets | 2,291,999 | 2,539,321 |
Current liabilities: | ||
Accounts payable | 13,630 | 10,451 |
Deferred revenue (includes $6,473 and $10,309 from related parties) | 39,223 | 47,817 |
Accrued expenses and other current liabilities | 110,478 | 114,694 |
Total current liabilities | 163,331 | 172,962 |
Non-current liabilities: | ||
Deferred revenue, net of current portion (includes $132,799 and $131,188 from related parties) | 179,903 | 174,767 |
Operating lease liabilities, non-current | 410,938 | 413,256 |
Warrant liabilities | 14,146 | 10,868 |
Other non-current liabilities | 20,096 | 31,191 |
Total Liabilities | 788,414 | 803,044 |
Commitments and contingencies (Note 7) | ||
Shareholders' equity: | ||
Preferred stock, $0.0001 par value; 200,000,000 shares authorized; none issued | 0 | 0 |
Common stock, $0.0001 par value (Note 6) | 196 | 190 |
Additional paid-in capital | 6,280,632 | 6,136,378 |
Accumulated deficit | (4,775,943) | (4,397,659) |
Accumulated other comprehensive loss | (1,300) | (2,632) |
Total stockholders equity | 1,503,585 | 1,736,277 |
Total Liabilities and Shareholders' Equity | $ 2,291,999 | $ 2,539,321 |